DENTSPLY SIRONA (NASDAQ:XRAY) Updates FY 2025 Earnings Guidance

DENTSPLY SIRONA (NASDAQ:XRAY) updated its FY 2025 earnings guidance on Thursday. The company provided EPS guidance of 1.600-1.600 for the period, compared to the consensus EPS estimate of 1.870. The company issued revenue guidance of $3.6 billion-$3.7 billion, compared to the consensus revenue estimate of $3.7 billion.

DENTSPLY SIRONA Stock Performance

Shares of XRAY stock opened at $11.06 on Friday. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.11 and a current ratio of 1.69. The company has a market capitalization of $2.21 billion, a price-to-earnings ratio of -2.34, a price-to-earnings-growth ratio of 0.81 and a beta of 1.00. DENTSPLY SIRONA has a one year low of $10.69 and a one year high of $20.59. The company’s 50-day moving average is $13.04 and its 200 day moving average is $14.48.

DENTSPLY SIRONA (NASDAQ:XRAY) last announced its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $0.37 earnings per share for the quarter, missing analysts’ consensus estimates of $0.45 by ($0.08). DENTSPLY SIRONA had a positive return on equity of 16.33% and a negative net margin of 25.85%.The firm had revenue of $904.00 million during the quarter, compared to analysts’ expectations of $900.33 million. During the same quarter in the previous year, the firm earned $0.50 earnings per share. DENTSPLY SIRONA’s revenue was down 4.9% on a year-over-year basis. DENTSPLY SIRONA has set its FY 2025 guidance at 1.600-1.600 EPS. Sell-side analysts expect that DENTSPLY SIRONA will post 1.84 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms have commented on XRAY. Evercore ISI cut their target price on shares of DENTSPLY SIRONA from $17.00 to $13.00 and set an “in-line” rating for the company in a research report on Wednesday, October 8th. Stifel Nicolaus set a $13.00 price objective on DENTSPLY SIRONA in a research note on Thursday. Wells Fargo & Company decreased their price target on shares of DENTSPLY SIRONA from $16.00 to $15.00 and set an “equal weight” rating on the stock in a research note on Friday, August 8th. Barrington Research reissued an “outperform” rating and issued a $18.00 price objective on shares of DENTSPLY SIRONA in a research note on Wednesday, October 29th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of DENTSPLY SIRONA in a research report on Wednesday, October 8th. Two analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $17.55.

Institutional Investors Weigh In On DENTSPLY SIRONA

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in shares of DENTSPLY SIRONA in the 1st quarter valued at approximately $26,000. Goldman Sachs Group Inc. grew its stake in shares of DENTSPLY SIRONA by 827.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,434,925 shares of the medical instruments supplier’s stock worth $36,378,000 after purchasing an additional 2,172,343 shares during the period. Empowered Funds LLC grew its position in DENTSPLY SIRONA by 8.8% during the first quarter. Empowered Funds LLC now owns 16,324 shares of the medical instruments supplier’s stock valued at $244,000 after buying an additional 1,320 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in DENTSPLY SIRONA by 7.5% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 593,021 shares of the medical instruments supplier’s stock worth $8,860,000 after purchasing an additional 41,579 shares during the period. Finally, Focus Partners Wealth lifted its position in shares of DENTSPLY SIRONA by 59.1% during the 1st quarter. Focus Partners Wealth now owns 25,181 shares of the medical instruments supplier’s stock valued at $376,000 after buying an additional 9,355 shares in the last quarter. 95.70% of the stock is currently owned by hedge funds and other institutional investors.

About DENTSPLY SIRONA

DENTSPLY SIRONA Inc manufactures and sells various dental products and technologies worldwide. It operates in four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The company offers dental equipment comprising imaging equipment, motorized dental handpieces, treatment centers, other instruments, amalgamators, mixing machines, and porcelain furnaces; and dental CAD/CAM technologies to support dental restorations, such as intraoral scanners, 3-D printers, mills, other software and services, and a full-chairside economical restoration of esthetic ceramic dentistry, as well as DS Core, its cloud-based platform.